UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, DC 20549





FORM 10-Q





(Mark one)


x
QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period endedMarch 31, 2009o
TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ______________ to _____________





Commission File No. 000-51731







NATIONAL HEALTH PARTNERS, INC.(Exact name of registrant as specified in its charter)






Indiana

04-3786176(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)





120 Gibraltar Road


Suite 107


Horsham, PA  19044


(Address of Principal Executive Offices)





(215) 682-7114


(Issuer's Telephone Number, including Area Code)





Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1394 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes  x  No  o





Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes  o  No  o





Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.





Large accelerated filero

Accelerated fileroNon-accelerated filer o

(Do not check if a smaller reporting company)

Smaller reporting company x





Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act).  YesoNox





APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS





Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. YesoNoo





APPLICABLE ONLY TO CORPORATE ISSUERS





Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:  There were 84,392,478 shares of the issuer’s common stock, $.001 par value per share, issued and outstanding on May 14, 2010.





TABLE OF CONTENTS








PagePART I – FINANCIAL INFORMATIONItem 1. Financial Statements
1Consolidated Balance Sheets at March 31, 2010 (Unaudited) and December 31, 2009
1Consolidated Statements of Operations for the Three Months Ended March 31, 2010 and 2009 (Unaudited)
2Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2010 and 2009 (Unaudited)
3Notes to Consolidated Financial Statements (Unaudited)
4Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
10Item 4T. Controls and Procedures
17PART II – OTHER INFORMATIONItem 2. Unregistered Sales of Equity Securities and Use of Proceeds
17Item 5. Other Information.
18Item 6. Exhibits
18





PART I – FINANCIAL INFORMATION





Item 1.  Financial Statements.





National Health Partners, Inc. and Subsidiaries


Consolidated Balance Sheets








March 31,2010


December 31,(Unaudited)


2009AssetsCurrent assets:Cash

$
42,362


$
31,691Prepaid expense


—



4,699Deposits


78,829



78,829Other current assets


—



9,300Total current assets


121,191



124,519Property and equipment, net


12,881



15,743Prepaid expense


—



1,357Deposits


19,000



19,000Total assets

$
153,072


$
160,619Liabilities and stockholders' deficitCurrent liabilitiesAccounts payable

$
108,422


$
144,369Refunds payable


10,798



8,607Accrued expenses


752



892Deferred revenue


112,798



92,188Total current liabilities


232,770



246,056Total liabilities


232,770



246,056Commitments and contingenciesStockholders' deficit:Common stock, $0.001 par value, 100,000,000 shares authorized,

84,392,478 and 73,894,754 sharesissued and outstanding on

March 31, 2010 and December 31, 2009, respectively


84,392



73,895Additional paid-in capital


26,874,307



26,554,571Deferred compensation


(87,579
)


(106,060
)Accumulated deficit


(26,950,818
)


(26,607,843
)Total stockholders' deficit


(79,698
)


(85,437
)Total liabilities and stockholders' deficit

$
153,072


$
160,619














The accompanying notes are an integral part of these consolidated financial statements


1


National Health Partners, Inc. and Subsidiaries


Consolidated Statements of Operations (Unaudited)








For the Three Months EndedMarch 31,2010


2009Net revenue

$
537,810


$
417,843Direct costs


245,639



131,944Gross profit


292,171



285,899Operating expenses:Selling and marketing


10,878



36,041General and administrative


624,268



715,218Total operating expenses


635,146



751,259Loss from operations


(342,975
)


(465,360
)Other income (expense):Interest income


—



83Total other income (expense)


—



83Net loss

$
(342,975
)

$
(465,277
)Loss per share - basic and diluted

$
(0.00
)

$
(0.01
)Weighted average number of shares outstanding - basic and diluted


77,083,643



53,145,170














The accompanying notes are an integral part of these consolidated financial statements


2


National Health Partners, Inc. and Subsidiaries


Consolidated Statements of Cash Flows (Unaudited)








For the Three Months EndedMarch 31,2010


2009Cash flows from operating activitiesNet loss

$
(342,975
)

$
(465,277
)Adjustments to reconcile net loss to net cash used by operating activities:Common stock issued for services and amortization of prepaid services


87,045



98,383Options issued for services


73,600



68,151Depreciation


2,862



7,246Changes in operating assets and liabilities:Decrease in deposits


—



8,511Decrease in other current assets


9,300



—(Decrease) increase in accounts payable and accrued expenses


(36,087
)


119,942Increase in refunds payable


2,191



4,732Increase (decrease) in deferred revenue


20,610



(21,510
)Net cash used by operating activities


(183,454
)


(179,822
)Cash flows from investing activitiesNet cash provided by investing activities


—



—Cash flows from financing activitiesProceeds from sale of stocks and warrants


194,125



6,000Net cash provided by financing activities


194,125



6,000Net increase (decrease) in cash


10,671



(173,822
)Cash at beginning of period


31,691



177,545Cash at end of period

$
42,362


$
3,723Supplemental disclosure of cash flow informationCash paid for interest

$
—


$
—Cash paid for taxes

$
—


$
—Schedule of non-cash financing activitiesCommon stock issued for stock offering costs

$
285


$
—














The accompanying notes are an integral part of these consolidated financial statements


3


National Health Partners, Inc. and Subsidiaries


Notes to Consolidated Financial Statements


March 31, 2010


(Unaudited)





Note 1. Description of Business





National Health Partners, Inc. (the “Company”) was organized on March 10, 1989 as “Spectrum Vision Systems of Indiana, Inc.” under the laws of the State of Indiana.  The Company changed its name to “National Health Partners, Inc.” on March 13, 2001.





The Company sells membership programs that encompass all aspects of healthcare, including physicians, hospitals, ancillary services, dentists, prescription drugs and vision care through a national healthcare savings network called “CARExpress.”  The Company derives almost all of its revenue from the monthly membership fees it receives from its members.  It markets its programs through a direct sales force, brokers and agents, unions and associations, chambers of commerce, and a variety of other organizations.  The Company typically pays these organizations commissions on the sale price of the membership programs.  These organizations typically offer and sell the Company’s membership programs on a part-time basis and may engage in other related or unrelated business activities, including selling the products or services of the Company’s competitors.  The Company’s agreements with these organizations are generally for a term of one year and renew automatically for additional one-year terms unless written notice of termination is delivered by either party to the other at least 30 days prior to the then-current term.





The Company contracts with preferred provider organizations and other provider networks for access to the discounted rates they have negotiated with their healthcare providers.  The principal suppliers of the healthcare providers that comprise CARExpress are CareMark, Aetna, Optum, Outlook Vision, Integrated Health, Three Rivers and HealthFi.  The Company selects and utilizes only those provider networks that it believes can deliver adequate savings to its members while providing adequate support for its membership programs with the healthcare providers.  It typically pays a per member per month fee for use of the provider networks that is determined in part based on the number of providers participating in the network, the number of members accessing the network, and the particular products or services offered by the providers.  The Company’s agreements with the provider networks are generally for a term of between one and two years, may be terminated by either party on between 45 and 180 days’ prior written notice, and renew automatically for additional terms unless so terminated.  Most of these agreements are non-exclusive and contain confidentiality provisions.





Note 2. Basis of Presentation





The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and in conformity with the instructions to Form 10-Q and Article 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (the “SEC”).  Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, the disclosures included in these financial statements are adequate to make the information presented not misleading.




The unaudited consolidated financial statements included in this document have been prepared on the same basis as the annual consolidated financial statements and in management’s opinion, reflect all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2009 included in the Company’s Annual Report on Form 10-K.  The results of operations for the three months ended March 31, 2010 are not necessarily indicative of the results that the Company will have for any subsequent quarter or full fiscal year.





The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.  The financial  tatements include the balances of National Health Partners, Inc. and its wholly-owned subsidiaries.  All material inter-company balances and transactions have been eliminated in consolidation.


4
 National Health Partners, Inc. and Subsidiaries
 Notes to Consolidated Financial Statements
 March 31, 2010
 (Unaudited)


Note 2. Basis of Presentation (Continued)





The Company’s financial statements have been prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has historically incurred significant losses, which raises substantial doubt about the Company’s ability to continue as a going concern.  The accompanying financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.





As of March 31, 2010, the Company’s significant accounting policies and estimates, which are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, have not changed materially.





Note 3. Stock Compensation Expense





The Company records employee stock-based compensation using the fair value recognition provisions of Accounting Standards Codification (“ASC”) Topic 718 (“ASC 718”) using the modified prospective transition method, and records non-employee stock-based compensation expense in accordance with ASC Topic 505.  In accordance therewith, the Company recognized stock compensation expense of $24,536 and $98,383 for the three months ended March 31, 2010 and 2009, respectively.





Note 4. Loss Per Share





Basic loss per share is based on the weighted average number of shares of the Company’s common stock outstanding during the applicable period, and is calculated by dividing the reported net loss for the applicable period by the weighted average number of shares of common stock outstanding during the applicable period.  The Company calculates diluted loss per share by dividing the reported net loss for the applicable period by the weighted average number of shares of common stock outstanding during the applicable period as adjusted to give effect to the exercise of all potentially dilutive options and warrants outstanding at the end of the period.  A total of 15,450,515 and 18,564,750 shares of common stock underlying options and warrants that were outstanding on March 31, 2010 and 2009, respectively, have been excluded from the computation of diluted earnings per share because they are anti-dilutive.  As a result, basic loss per share was equal to diluted loss per share for each period.




For the Three Months

Ended March 31,2010


2009Net loss as reported

$
(342,975
)

$
(465,277
)Weighted average number of shares outstanding - basic and diluted


77,083,643



53,145,170Loss per share - basic and diluted

$
(0.00
)

$
(0.01
)


Note 5. Property and Equipment




Property and equipment consisted of the following at March 31, 2010:
 
 Asset


AmountComputers

$
60,708Software

6,109Furniture

27,968Telephone

80,780Website

106,477Less: accumulated depreciation

(269,161
)Net property and equipment

$
12,881
 Depreciation expense was $2,862 and $7,246 for the three months ended March 31, 2010 and 2009, respectively.


5
 National Health Partners, Inc. and Subsidiaries
 Notes to Consolidated Financial Statements
 March 31, 2010
 (Unaudited)


Note 6. Deposits





Deposits consist of cash reserves held by merchant processors that the Company uses to process credit card transactions and the security deposit held by the lessor of the Company’s office space.  Each agreement that the Company has entered into with merchant processors contains a standard provision that gives the merchant processors the right to withhold funds from the proceeds generated by the Company through the sale of its membership programs through credit card transactions.  The amount of the reserves may be increased or decreased by each merchant processor at any time based on the perceived risk exposure of the merchant processor.  The merchant processors are required to return the amount of funds that they withhold from the proceeds within no less than six months and no more than nine months of the date such funds were originally withheld.  As a result, the Company expects to receive all such funds within six to nine months of the date such funds were originally withheld by the merchant processors.





As of March 31, 2010, the Company had a total of $97,829 in deposits.  Of this amount, $75,000 was being held by PowerPay Payment Systems, Inc., $2,829 was being held by PayTran Payment Systems, $1,000 was being held by Clickbooth.com and $19,000 was being held by the lessor of the Company’s office space.





Note 7. Commitments and Contingencies





The Company’s material commitments and contingencies consist of an operating lease for its office space in Pennsylvania and employment agreements with its executive officers.





Operating Leases





The Company is a party to a lease for its office facility located in Horsham, Pennsylvania which was most recently amended on November 13, 2009.  The amendment extended the term of the lease from May 31, 2010 to May 31, 2013.  The amendment provides for an initial monthly rent payment of $7,214 and an initial monthly operating expense payment of approximately $6,160.  The Company will be required to make minimum annual rent payments of approximately $86,500, $90,000 and $93,500, respectively, and estimated annual operating expense payments of approximately $74,000 (subject to periodic increases) during the three-year term of the amendment.




Future minimum lease payments under this facility lease are as follows:
 
 Fiscal Year


Amount2010

$
160,5002011

164,0002012

167,5002013

69,792$
561,792
 
 Employment Agreements
 
 The Company is a party to an employment agreement with its current executive officer.  At the request of the executive officer, the Company resolved to decrease the annual salary in the employment agreement to $168,000, effective February 1, 2010.  Future minimum payments under this employment agreement are as follows:
 
 Fiscal Year


Amount2010

$
185,6902011

168,000$
353,690


6
 National Health Partners, Inc. and Subsidiaries
 Notes to Consolidated Financial Statements
 March 31, 2010
 (Unaudited)





Note 8. 2006 Stock Incentive Plan





On February 2, 2006, the Company adopted the National Health Partners, Inc. 2006 Stock Incentive Plan.  Under the plan, 4,500,000 shares of common stock may be granted to employees, officers and directors of, and consultants and advisors to, the Company under awards that may be made in the form of stock options, warrants, stock appreciation rights, restricted stock, restricted units, unrestricted stock and other equity-based or equity-related awards.  As of March 31, 2010, all shares of common stock had been issued under the plan.  The plan terminates on February 1, 2016.  On February 6, 2006, the Company filed a registration statement on Form S-8, File No. 333-131589, with the SEC covering the public sale of the 4,500,000 shares of common stock available for issuance under the plan.





Note 9. 2008 Stock Incentive Plan





On April 7, 2008, the Company adopted the National Health Partners, Inc. 2008 Stock Incentive Plan.  Under the plan, 3,000,000 shares of common stock may be granted to employees, officers and directors of, and consultants and advisors to, the Company under awards that may be made in the form of stock options, warrants, stock appreciation rights, restricted stock, restricted units, unrestricted stock and other equity-based or equity-related awards.  As of March 31, 2010, all shares of common stock had been issued under the plan.  The plan terminates on April 6, 2018.  On April 10, 2008, the Company filed a registration statement on Form S-8, File No. 333-150177, with the SEC covering the public sale of the 3,000,000 shares of common stock available for issuance under the plan.





Note 10. 401(k) Plan





On January 15, 2007, the Company adopted the National Health Partners, Inc. 401(k) Plan. Under the plan, eligible employees may elect to contribute up to 100% of their compensation to the plan each year, subject to certain limitations imposed by the Internal Revenue Service.  The Company contributes 100% of the first 3% of the employee’s contribution and 50% of the next 2% of the employee’s contribution. The Company contributed $60 and $2,833 to the plan during the three months ended March 31, 2010 and 2009, respectively.





Note 11. Common Stock and Warrants





The Company’s authorized capital consisted of 100,000,000 shares of common stock, $0.001 par value per share, at March 31, 2010 and 2009, respectively, of which 84,392,478 and 53,286,281 shares of common stock were outstanding at March 31, 2010 and 2009, respectively.  Warrants exercisable into an aggregate of 11,143,372 and 3,969,217 shares of the Company’s common stock were outstanding on March 31, 2010 and 2009, respectively.





Non Capital-Raising Transactions





On March 31, 2010, the Company entered into a Securities Agreement with David M. Daniels, its Chief Executive Officer, pursuant to which it granted 1,180,612 shares of the Company’s common stock, $0.001 par value per share to Mr. Daniels.  The shares were issued in lieu of the payment of $17,690 of salary compensation earned by Mr. Daniels under the Employment Agreement, dated May 1, 2006, by and between the Company and Mr. Daniels, during the period commencing January 1, 2010 and ending January 31, 2010 and payable to Mr. Daniels as of January 31, 2010, and in part for the termination of the following stock options held by Mr. Daniels: (i) the stock option dated February 1, 2005 to acquire 2,500,000 shares of common stock at an exercise price of $0.40, (ii) the stock option dated December 12, 2006 to acquire 250,000 shares of common stock at an exercise price of $0.88, and (iii) the stock option dated March 25, 2008 to acquire 400,000 shares of common stock at an exercise price of $0.28.





On March 31, 2010, the Company entered into a Securities Agreement with Patricia S. Bathurst, its Vice President — Marketing,  pursuant to which it granted a stock option (the “Option”) to acquire 500,000 shares of common stock to Ms. Bathurst.  The Option was issued in lieu of the payment of $8,119 of salary compensation earned by Ms. Bathurst under the Employment Agreement, dated May 1, 2006, by and between the Company and Ms. Bathurst during the period commencing January 1, 2010 and ending January 31, 2010 and payable to Ms. Bathurst as of January 31, 2010, and in part for the termination of the following stock options held by Ms. Bathurst: (i) the stock option dated February 1, 2005 to acquire 2,500,000 shares of common stock at an exercise price of $0.40, (ii) the stock option dated December 12, 2006 to acquire 250,000 shares of common stock at an exercise price of $0.88, (iii) the stock option dated September 4, 2007 to acquire 400,000 shares of common stock at an exercise price of $0.50, and (iv) the stock option dated March 25, 2008 to acquire 400,000 shares of common stock at an exercise price of $0.28.  The Option is for a term of 10 years, has an exercise price of $0.045 per share and vested in full on the date of grant.





7


National Health Partners, Inc. and Subsidiaries
 Notes to Consolidated Financial Statements
 March 31, 2010
 (Unaudited)
 
 Note 11. Common Stock and Warrants (Continued)




On March 31, 2010, the Company entered into a Securities Agreement with Alex Soufflas, its Chief Financial Officer and Executive Vice President,  pursuant to which it granted 382,112 shares of common stock to Mr. Soufflas.  The shares were issued in lieu of the payment of $14,765 of salary compensation earned by Mr. Soufflas under the Employment Agreement, dated February 1, 2006, by and between the Company and Mr. Soufflas, during the period commencing January 1, 2010 and ending January 31, 2010 and payable to Mr. Soufflas as of January 31, 2010.





Capital-Raising Transactions





In January 2010, we sold 1,000,000 shares of our common stock and Class A warrants exercisable into 1,000,000 shares of our common stock to an accredited investor for aggregate gross proceeds of $40,000.  The Class A warrants have an exercise price of $0.04 per share, are exercisable during the period commencing on the date of grant and ending December 31, 2010, and expire at the end of the exercise period.





In February 2010, we sold 2,000,000 shares of our common stock to an accredited investor for aggregate gross proceeds of $40,000.





In February 2010, we sold 2,000,000 shares of our common stock and Class A warrants exercisable into 4,000,000 shares of our common stock to an accredited investor for aggregate gross proceeds of $40,000.  The Class A warrants have an exercise price of $0.02 per share, are exercisable during the period commencing on the date of grant and ending December 31, 2010, and expire at the end of the exercise period.





In March 2010, we completed a private offering of 450,000 shares of our common stock for aggregate cash consideration of $10,125.





In March 2010, we completed a private offering of 3,200,000 shares of our common stock for aggregate cash consideration of $64,000.





Note 12. Stock Options





Stock options exercisable into an aggregate of 4,307,143 and 9,176,500 shares of the Company’s common stock were outstanding on March 31, 2010 and 2009, respectively, of which 4,010,286 and 7,159,000 shares were vested, respectively.  No options were exercised during the three months ended March 31, 2010 and 2009, respectively.  The Company estimates the fair value of its stock options on the date of grant by using the Black-Scholes pricing model in accordance with the provisions of Statement of Financial Accounting Standards No. 148, “Accounting for Stock-Based Compensation — Transition and Disclosure.”  Under the Black-Scholes pricing model, the Company used the following weighted-average assumptions to determine the fair value of the stock options issued: a dividend yield of zero percent, an expected volatility of between 219% and 282%, a risk-free interest rate of between 2.25% and 4.76% and a remaining contractual life of between 9.15 and 9.95 years.





Note 13. Related Party Transactions





On March 31, 2010, the Company entered into a Securities Agreement with David M. Daniels, its Chief Executive Officer, pursuant to which it granted 1,180,612 shares of the Company’s common stock, $0.001 par value per share to Mr. Daniels.  The shares were issued in lieu of the payment of $17,690 of salary compensation earned by Mr. Daniels under the Employment Agreement, dated May 1, 2006, by and between the Company and Mr. Daniels, during the period commencing January 1, 2010 and ending January 31, 2010 and payable to Mr. Daniels as of January 31, 2010, and in part for the termination of the following stock options held by Mr. Daniels: (i) the stock option dated February 1, 2005 to acquire 2,500,000 shares of common stock at an exercise price of $0.40, (ii) the stock option dated December 12, 2006 to acquire 250,000 shares of common stock at an exercise price of $0.88, and (iii) the stock option dated March 25, 2008 to acquire 400,000 shares of common stock at an exercise price of $0.28.


8
 National Health Partners, Inc. and Subsidiaries
 Notes to Consolidated Financial Statements
 March 31, 2010
 (Unaudited)


Note 13. Related Party Transactions (Continued)





On March 31, 2010, the Company entered into a Securities Agreement with Patricia S. Bathurst, its Vice President — Marketing, pursuant to which it granted a stock option (the “Option”) to acquire 500,000 shares of common stock to Ms. Bathurst.  The Option was issued in lieu of the payment of $8,119 of salary compensation earned by Ms. Bathurst under the Employment Agreement, dated May 1, 2006, by and between the Company and Ms. Bathurst during the period commencing January 1, 2010 and ending January 31, 2010 and payable to Ms. Bathurst as of January 31, 2010, and in part for the termination of the following stock options held by Ms. Bathurst: (i) the stock option dated February 1, 2005 to acquire 2,500,000 shares of common stock at an exercise price of $0.40, (ii) the stock option dated December 12, 2006 to acquire 250,000 shares of common stock at an exercise price of $0.88, (iii) the stock option dated September 4, 2007 to acquire 400,000 shares of common stock at an exercise price of $0.50, and (iv) the stock option dated March 25, 2008 to acquire 400,000 shares of common stock at an exercise price of $0.28.  The Option is for a term of 10 years, has an exercise price of $0.045 per share and vested in full on the date of grant.





On March 31, 2010, the Company entered into a Securities Agreement with Alex Soufflas, its Chief Financial Officer and Executive Vice President, pursuant to which it granted 382,112 shares of common stock to Mr. Soufflas.  The shares were issued in lieu of the payment of $14,765 of salary compensation earned by Mr. Soufflas under the Employment Agreement, dated February 1, 2006, by and between the Company and Mr. Soufflas, during the period commencing January 1, 2010 and ending January 31, 2010 and payable to Mr. Soufflas as of January 31, 2010.





Note 14.  Subsequent Events





The Company has performed an evaluation of subsequent events in accordance with ASC Topic 855.  Other than the events noted below, the Company is not aware of any subsequent events which would require recognition or disclosure in the financial statements.





The registration statement filed by the Company on March 31, 2010 with the SEC,  to register the resale of 3,935,000 shares of common stock sold or issued in two offerings during March 2010, was deemed Effective by the SEC on April 23, 2010.


9


DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS





This report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  All statements other than statements of historical facts included or incorporated by reference in this report, including, without limitation, statements regarding our future financial position, business strategy, budgets, projected revenue and costs, and plans and objectives of management for future operations, are forward-looking statements.  In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expects,” “intends,” “plans,” “projects,” “estimates,” “anticipates,” or “believes” or the negative thereof or any variation thereon or similar terminology or expressions.




These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements.  Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to have been correct.  Important factors that could cause actual results to differ materially from our expectations include, but are not limited to:





·
our ability to fund future growth and implement our business strategy;




·
our dependence on a limited number of preferred provider organizations (“PPOs”) and other healthcare provider networks;




·
our dependence on a single insurance company for the insurance benefits offered as part of our CARExpress PlusTM programs;




·
our dependence upon a limited number of marketing and distribution partners for substantially all of our revenue;




·
our ability to market our membership programs and develop and expand the market for our membership programs;




·
demand for and acceptance of our membership programs;




·
competition in the health discount membership market;




·
our ability to attract and retain qualified personnel;




·
legislative or regulatory changes in the healthcare industry;




·
the condition of the securities and capital markets;




·
general economic and business conditions, either nationally or internationally or in the jurisdictions in which we are doing business;




and statements of assumption underlying any of the foregoing, as well as any other factors set forth herein under “Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations” below and “Item 1A.  Risk Factors” of our Annual Report on Form 10-K for our fiscal year ended December 31, 2009.  All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing.  Except as required by law, we assume no duty to update or revise our forward-looking statements.




Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.








Unless otherwise indicated or the context otherwise requires, all references to the “Company,” the “registrant” “we,” “us” or “our” and similar terms in this report refer to National Health Partners, Inc. and its subsidiaries.




This Management’s Discussion and Analysis of Financial Condition and Results of Operations and other parts of this report contain forward-looking statements that involve risks and uncertainties.  All forward-looking statements included in this report are based on information available to us on the date hereof, and, except as required by law, we assume no obligation to update any such forward-looking statements.  Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth herein and under the caption “Item 1A.  Risk Factors” in our Annual Report on Form 10-K for our fiscal year ended December 31, 2009.  The following should be read in conjunction with our consolidated financial statements included above in Item 1 of Part I of this report.




10





Overview




We are a national healthcare membership organization that was formed to address the need for affordable healthcare nationwide.  We create, market and sell membership programs to predominantly underserved markets in the healthcare industry through a national healthcare savings network called CARExpressTM.  CARExpressTM is a network of hospitals, doctors, dentists, pharmacists and other healthcare providers comprised of over 1,000,000 healthcare providers that render their services and products to CARExpressTM members at discounted prices.  CARExpressTM enables people to engage in point-of-service transactions directly with these healthcare providers and pay discounted prices to the providers.





Our membership programs offer savings on healthcare services to persons who are uninsured or underinsured by providing them with access to the same PPOs that are utilized by employers that self-fund at least a portion of their employees’ healthcare costs.  Our membership programs are also used to supplement benefit plans and fill in the gaps created by the need to reduce health benefits to keep the costs of health insurance reasonable.  We sell our membership programs directly through our sales force and indirectly through brokers and agents, unions and associations, small businesses and other organizations.





We are actively engaged in marketing our membership programs to the public.  Our primary objective is to generate increased sales of our membership programs while expanding our position as a provider of unique healthcare membership service programs.  The target market for our membership programs is comprised of individuals who have either limited health benefits or no health benefits.  Our share of this market is currently less than one percent and has been less than one percent since our inception.  Since we are not currently large enough to pursue and support the entire market, we intend to continue to pursue specific opportunities that we identify in this market through our various marketing and distribution channels.  Through product design, competitive membership pricing, and a variety of marketing and distribution partners, we are pursuing opportunities in the healthcare market that insurance companies have not addressed.





Operational Metrics





Our revenue consists almost exclusively of recurring monthly membership fees that we receive from members of our membership programs.  Our members pay us membership fees each month for the duration of their membership.  The average membership fee per member per month that we receive for our CARExpressTM health discount programs is approximately $35.  Approximately 95% of the CARExpressTM health discount programs that we have sold to our current members consist of our Comprehensive Care Program which is currently sold at a monthly retail price of $39.95.  The remaining CARExpressTM health discount programs that we have sold to our current members consist of a mix of our less expensive programs.  Approximately 90% of the CARExpress PlusTM membership programs that we have sold to our current members consist of our CARExpress PlusTM Gold Program which is currently sold at a monthly retail price of $137.  The remaining CARExpress PlusTM membership programs that we have sold to our current members consist of a mix of our other programs.





We receive each member’s initial monthly payment and billing information at the beginning of the first monthly membership period.  Monthly payments for subsequent periods are received at the beginning of the applicable period.  The monthly membership fees that we receive are recognized as revenue evenly over the applicable monthly membership period.  As a result, there is a delay of four weeks between the date we receive a monthly membership fee and the date we recognize the entire fee as revenue.





A key metric that we use to evaluate our success is our member retention rates.  Member retention rates represent the percentage of new members that we acquire that we are able to retain for a specified period of time.  Since we incur a large portion of our costs up front and receive recurring membership fees throughout the term of the membership, the longer we are able to retain the members we acquire, the greater the revenue potential of the membership programs that we sell.  We believe that the key to obtaining a high member retention rate is to target our marketing campaigns towards those individuals and organizations that are most in need of our programs, most capable of paying for our programs, and most loyal to us and our programs.  Member retention rates can be influenced by a variety of factors, including:




11




·
the type of membership programs being sold;




·
the marketing campaign being used to sell our membership programs;




·
the financial condition and loyalty of our members;




·
the distribution channel selling our membership programs; and




·
the type and amount of compensation being paid to our marketing and distribution partners to sell our membership programs.





We have obtained valuable information regarding member demographics through the marketing and advertising campaigns that we have conducted and are focusing our marketing and advertising campaigns on members and member groups that we have identified as being most suitable for our membership programs.  As a result, we expect our retention rates to continue to improve over the next 12 months as we pursue these opportunities through our various marketing and distribution channels.





Financial Results and Outlook





Our strategy is to continue to expand our position as a provider of unique discount healthcare membership programs.  We have implemented several strategic growth initiatives during the past 12 months through which we achieved new contracts and strategic partnerships with a number of organizations, the most profound of which involved a shift in our sales strategy from sales through marketing companies to sales through employers and “affinity groups.”  An “affinity group” is a group of people who share interests, issues, and a common bond or background, and offer support for each other.  Examples of the types of affinity groups that we are working with include unions, associations, chambers of commerce and small business networks.  These organizations typically have a large number of members and thus, each one provides us with the opportunity to obtain a large number of sales.  In addition, it is far less costly for us to sell our CARExpressTM programs through these organizations than it is for us to engage in expensive, nation-wide marketing and advertising campaigns through marketing companies, and the members that we obtain through these sources tend to remain members for a much longer period of time.





We experienced an increase in revenue for the three months ended March 31, 2010 compared to the three months ended March 31, 2009 as a result of the shift in our sales strategy from sales through marketing companies to sales through employers and affinity groups.  The shift in our sales strategy resulted in increased direct costs in total and as a percentage of revenue.  However, our gross profit margin for the three months ended March 31, 2010 was lower than our gross profit margin for the three months ended March 31, 2009.  Similarly, our net loss and net loss per share for the three months ended March 31, 2010 were substantially lower than our net loss and net loss per share for the three months ended March 31, 2009.  The shift in our sales strategy and the implementation of cost-cutting initiatives also resulted in a slight increase in net cash used by operating activities during the three months ended March 31, 2010 compared to the three months ended March 31, 2009.





We generated revenue of $537,810 for the three months ended March 31, 2010 compared to revenue of $417,843 for the three months ended March 31, 2009.  We achieved a gross profit of $292,171 and gross profit percentage of 54% for the three months ended March 31, 2010, compared to a gross profit of $285,899 and gross profit margin of 68% for the three months ended March 31, 2009.  We recognized a net loss of $342,975, or $0.004 per share, for the three months ended March 31, 2010, compared to a net loss of $465,277, or $0.009 per share, for the three months ended March 31, 2009.  Net cash used by operating activities was $183,454 for the three months ended March 31, 2010 compared to $179,822 for the three months ended March 31, 2009, representing an increase of 2%.





We will generate future revenue and members primarily through sales of our CARExpressTM health discount programs and our CARExpress PlusTM membership programs to employees and members of affinity groups through our direct sales force, our marketing and distribution partners, and various marketing and advertising campaigns.  We have entered into agreements with several affinity groups through which we are generating sales of our CARExpressTM membership programs and are currently in discussions with several other organizations regarding the sale of our CARExpressTM membership programs.  We intend to finance each of these projects through cash on hand, internally generated cash flows from operating activities and, if necessary, proceeds from the issuance of equity securities.  We will use any additional investments that we receive to accelerate the expansion of each of our advertising campaigns and programs and increase sales of our membership programs.




12




We expect the number of CARExpressTM members generated each month to increase substantially during the quarter ended June 30, 2010 as a number of deals that we have either recently closed or that we expect to close begin to generate members for us.  We also expect the number of CARExpressTM members generated each month to continue to increase throughout the year and expect our retention rates to improve over the next 12 months since members generated through affinity groups have historically remained members of CARExpressTM for a much longer period of time than members generated through marketing companies.  As a result, we expect to generate revenue of between $4 million and $6 million during the year ended December 31, 2010.  We believe that this increase in revenue combined with the various cost-cutting initiatives that we implemented over the past few quarters will enable us to generate positive cash flows from operating activities during the year ended December 31, 2010 as the recurring membership fees from our increasing membership base overtake the costs associated with retaining existing members and obtaining new members.  We can provide no assurance, however, that our membership base will increase as projected, that our member retention rates will improve over the next 12 months, that we will generate the aforementioned projected revenue, or that we will generate positive cash flows from operating activities during the year ended December 31, 2010.





Critical Accounting Policies





For information regarding our critical accounting policies, please refer to the discussion provided in our Annual Report on Form 10-K for our fiscal year ended December 31, 2009 under the caption “Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies” and our Notes to Consolidated Financial Statements included therein.





Recent Accounting Pronouncements





For information regarding recent accounting pronouncements applicable to our business, please refer to the discussion provided in our Annual Report on Form 10-K for our fiscal year ended December 31, 2009 under the caption “Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations – Recent Accounting Pronouncements” and our Notes to Consolidated Financial Statements included therein.





Comparison of the Three-Month Periods Ended March 31, 2010 and 2009





Revenue





Revenue consists almost exclusively of the monthly membership fees that we receive from members of our membership programs.  Revenue increased $119,967 to $537,810 for the three months ended March 31, 2010 from $417,843 for the three months ended March 31, 2009.





The increase of $119,967 resulted primarily from an increase in sales through employers and affinity groups in connection with the shift in our sales strategy from sales through marketing companies to sales through employers and affinity groups. The remainder of the revenue that we generated during these periods was derived from existing members.  We expect revenue to increase over the next 12 months as a result of increased sales to employees and members of affinity groups through our direct sales force, our marketing and distribution partners and our various marketing and advertising campaigns.





Direct Costs





Direct costs consist of sales commissions that we pay to our marketing and distribution partners and fees that we pay to our PPOs and provider networks for access to their networks.  Direct costs increased $113,695 to $245,639 for the three months ended March 31, 2010, from $131,944 for the three months ended March 31, 2010.  The increase of $113,695 was due to increases of $96,015 for sales commissions and $17,680 for PPO and provider network costs resulting from the increase in sales of our membership programs.  We expect cost of sales to increase over the next 12 months as increased sales of our membership programs result in higher overall sales commission expenses and provider network costs.




13




Selling and Marketing Expenses





Selling and marketing expenses consist of advertising expenses, marketing expenses, salaries and other compensation paid to employees selling and marketing our membership programs, rent expense allocated to our selling and marketing activities, depreciation and amortization expense allocated to our selling and marketing activities, and all other selling and marketing expenses incurred by us.  Selling and marketing expenses decreased $25,163 to $10,878 for the three months ended March 31, 2010, from $36,041 for the three months ended March 31, 2009.  The decrease of $25,163 was due primarily to a decrease of $21,524 for salaries and other compensation paid to employees selling and marketing our membership programs.  We expect selling and marketing expenses to increase during the next 12 months as we grow our direct sales force and engage in larger and more frequent marketing and advertising campaigns and activities.





General and Administrative Expenses





General and administrative expenses consist primarily of employee compensation expense, professional fees and other general and administrative expenses.





Employee Compensation Expense.  Employee compensation expense consists of all salaries and other cash compensation, equity-based compensation, 401(k) contributions and other compensation that we pay to our employees and the related payroll taxes that are not associated with our selling and marketing activities.  Employee compensation expense decreased $74,048 to $405,097 for the three months ended March 31, 2010, from $479,145 for the three months ended March 31, 2009.  The decrease of $74,048 was due  to decreases of $82,448 for salary expense,  $24,124 for restricted stock award expense, $7,620 for stock option expense and $5,634 for related payroll taxes offset by an increase of $42,495 for other employee compensation.  We expect employee compensation expense to increase over the next 12 months as we begin to hire additional employees to support the growth of our business.





Professional Fees.  Professional fees consist of fees paid to our independent accountants, lawyers, technology consultants and other professionals and consultants.  Professional fees decreased $41,884 to $57,886 for the three months ended March 31, 2010 from $99,770 for the three months ended March 31, 2009.  The decrease of $41,884 was due primarily to a decrease of $49,722 for the amount of expense recognized in connection with equity-based compensation paid to service providers and consultants for various services, offset by an increase of $7,145 in accounting fees.  We expect professional fees to increase over the next 12 months as we incur additional legal, accounting and technology fees in connection with the general expansion of our business and operations.





Other General and Administrative Expenses.  Other general and administrative expenses consist of office supplies expense, computer hardware and system costs, bank service charges, filing fees and dues, non-employee customer service representative expense, rent expense, health insurance and other related benefit costs, financial printer costs, transfer agent costs, the costs of investor relations campaigns and activities, postage and delivery expenses, severance expenses, general business expenses and miscellaneous general and administrative expenses that are not associated with our selling and marketing activities.  Other general and administrative expenses increased $24,992 to $161,285 for the three months ended March 31, 2010 from $136,303 for the three months ended March 31, 2009.  The increase of $24,992 resulted primarily from increases of $16,361 for credit card service charges associated with new and recurring member transactions, $4,673 for maintenance agreements and $4,504 for rent expense.  We expect other general and administrative expenses to increase over the next 12 months as we continue to incur expenses for bank service charges, financial printer services, investor relations campaigns and activities, transfer agent fees, health insurance, rent, non-employee customer service representatives, supplies, computer hardware and systems, and other miscellaneous items associated with the general operation and growth of our business.





Net Loss





Our net loss decreased $122,302 to $342,975 for the three months ended March 31, 2010, from $465,277 for the three months ended March 31, 2009.  The decrease of $122,302 was primarily due to decreases of $25,163 for selling and marketing expenses, $74,048 for employee compensation expenses and $41,884 for professional fees, offset by increases of $119,167 for revenue, $113,695 for direct costs incurred in connection with the sale of our membership programs and $24,992  for other general and administrative expenses. We expect to begin generating a net profit from operations during 2010 as the recurring membership fees from our increasing membership base overtake the costs associated with obtaining and retaining members.




14




Liquidity and Capital Resources





Since our inception, we have funded our operations primarily through private sales of equity securities.  As of March 31, 2010, we had cash and cash equivalents of  $42,362.





Net cash used by operating activities was $183,454 for the three months ended March 31, 2010, compared to $179,822 for the three months ended March 31, 2009.  The $3,632 increase in cash used by operating activities was due primarily to a decrease of $122,302 for net loss,  a decrease of $156,029 for accounts payable and accrued expenses and an increase of $42,120 for deferred revenue.





We did not have any cash flows from investing activities for the three months ended March 31, 2010 and 2009.





Net cash provided by financing activities was $194,125 for the three months ended March 31, 2010, compared to $6,000 for the three months ended March 31, 2009.  The $188,125 increase in cash provided by financing activities was due solely to the increase in proceeds from the sale of stock and warrants.





Our primary sources of capital over the past 12 months are set forth below.





In April 2009, the Company completed a private offering of 5,346,000 shares of its common stock and Class A warrants exercisable into 2,673,000 shares of common stock for aggregate cash consideration of $200,475.  The shares were sold in units consisting of two shares of common stock and one Class A warrant at a purchase price of $0.075 per unit.   The Company paid finder fees consisting of 400,900 units identical to the units sold in the offering.  The Class A warrants had an exercise price of $0.075 per share, were exercisable during the period commencing on the date of grant and ending September 30, 2009, and expired at the end of the exercise period.





In May 2009, the Company sold 2,000,000 shares of common stock and Class A warrants exercisable into 1,000,000 shares of common stock to an accredited investor for aggregate gross proceeds of $100,000.  The Company paid finder fees consisting of 200,000 shares of common stock and 100,000 Class A warrants.  The Class A warrants had an exercise price of $0.075 per share, were exercisable during the period commencing on the date of grant and ending December 31, 2009, and expired at the end of the exercise period.





In July 2009, the Company completed a private offering of 500,000 shares of its common stock and Class A warrants exercisable into 250,000 shares of common stock for aggregate cash consideration of $30,000.  The shares were sold in units consisting of two shares of common stock, one Class A warrant and one Class B warrant at a purchase price of $0.12 per unit.   The Class A warrants had an exercise price of $0.06 per share, were exercisable during the period commencing on the date of grant and ending December 31, 2009, and expired at the end of the exercise period.





In July 2009, the Company sold 2,000,000 shares of common stock and Class A warrants exercisable into 2,000,000 shares of common stock to an accredited investor for aggregate gross proceeds of $100,000.  The Company paid finder fees consisting of 200,000 shares of common stock.  The Class A warrants have an exercise price of $0.05 per share, are exercisable during the period commencing on the date of grant and ending December 31, 2010, and expire at the end of the exercise period.





In August 2009, the Company completed a private offering of 2,150,000 shares of its common stock, Class A warrants exercisable into 1,075,000 shares of common stock and Class B warrants exercisable into 1,075,000 shares of common stock for aggregate cash consideration of $107,500.  The shares were sold in units consisting of two shares of common stock, one Class A warrant and one Class B warrant at a purchase price of $0.10 per unit.   The Class A warrants had an exercise price of $0.05 per share, were exercisable during the period commencing on the date of grant and ending December 31, 2009, and expired at the end of the exercise period.   The Class B warrants have an exercise price of $0.10 per share, are exercisable during the period commencing on the date of grant and ending December 31, 2010, and expire at the end of the exercise period.




15




In October 2009, the Company completed a private offering of 1,004,560 shares of its common stock and Class A warrants exercisable into 502,280 shares of common stock for aggregate cash consideration of $50,228.  The shares were sold in units consisting of two shares of common stock and one Class A warrant at a purchase price of $0.10 per unit.   The Company paid finder fees consisting of 150,684 shares of common stock and Class A warrants exercisable into 75,342 shares of common stock.  The Class A warrants have an exercise price of $0.05 per share, are exercisable during the period commencing on the date of grant and ending May 31, 2010, and expire at the end of the exercise period.





In November 2009, the Company completed a private offering of 700,000 shares of its common stock and Class A warrants exercisable into 350,000 shares of common stock for aggregate cash consideration of $35,000.  The shares were sold in units consisting of two shares of common stock and one Class A warrant at a purchase price of $0.10 per unit.   The Company paid finder fees consisting of 105,000 shares of common stock and Class A warrants exercisable into 52,500 shares of common stock.  The Class A warrants have an exercise price of $0.05 per share, are exercisable during the period commencing on the date of grant and ending May 31, 2010, and expire at the end of the exercise period.





In November 2009, the Company completed a private offering of Class A warrants exercisable into 2,000,000 shares of common stock for aggregate cash consideration of $1,000.  The Company paid finder fees consisting of Class A warrants exercisable into 300,000 shares of common stock.  The Class A warrants had an exercise price of $0.04 per share, were exercisable during the period commencing on the date of grant and ending December 31, 2009, and expired at the end of the exercise period.





In November 2009, the Company sold 1,000,000 shares of common stock and Class A warrants exercisable into 1,000,000 shares of common stock to an accredited investor for aggregate gross proceeds of $50,000.  The Company paid finder fees consisting of 150,000 shares of common stock and Class A warrants exercisable into 150,000 shares of common stock.  The Class A warrants have an exercise price of $0.05 per share, are exercisable during the period commencing on the date of grant and ending December 31, 2010, and expire at the end of the exercise period.





During the year ended December 31, 2009, the Company received aggregate gross proceeds of $3,750 from the exercise of warrants held by one of the Company’s security holders.  The Company issued a total of 75,000 shares of its common stock in connection therewith at an exercise price of $0.05 per share.





In January 2010, we sold 1,000,000 shares of our common stock and Class A warrants exercisable into 1,000,000 shares of our common stock to an accredited investor for aggregate gross proceeds of $40,000.  The Class A warrants have an exercise price of $0.04 per share, are exercisable during the period commencing on the date of grant and ending December 31, 2010, and expire at the end of the exercise period.





In February 2010, we sold 2,000,000 shares of our common stock to an accredited investor for aggregate gross proceeds of $40,000.





In February 2010, we sold 2,000,000 shares of our common stock and Class A warrants exercisable into 4,000,000 shares of our common stock to an accredited investor for aggregate gross proceeds of $40,000.  The Class A warrants have an exercise price of $0.02 per share, are exercisable during the period commencing on the date of grant and ending December 31, 2010, and expire at the end of the exercise period.





In March 2010, we completed a private offering of 450,000 shares of our common stock for aggregate cash consideration of $10,125.





In March 2010, we completed a private offering of 3,200,000 shares of our common stock for aggregate cash consideration of $64,000.





To date, our capital needs have been met primarily through sales of equity securities and proceeds received upon the exercise of warrants held by our security holders.   We do not currently maintain a line of credit or term loan with any commercial bank or other financial institution.  We have used the proceeds from the exercise of warrants and our private offerings of securities to pay virtually all of the costs and expenses we have incurred.  These costs and expenses were comprised of operating expenses, which consisted of the employee compensation expenses, professional fees and other general and administrative expenses discussed above, and the costs of sales discussed above to the extent such costs of sales exceeded our revenue.




16




We believe that our current cash resources will not be sufficient to sustain our current operations for the next 12 months.  We will need to obtain additional cash resources within the next 12 months to enable us to pay our ongoing costs and expenses as they are incurred and finance the growth of our business.  We intend to obtain these funds through internally generated cash flows from operating activities and proceeds from the issuance of equity securities.  The issuance of additional equity would result in dilution to our existing shareholders.  We have not made arrangements to obtain additional financing and we can provide no assurance that additional financing will be available in an amount or on terms acceptable to us, if at all.  If we are unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms favorable to us, we may be unable to execute upon our business plan or pay our costs and expenses as they are incurred, which could have a material, adverse effect on our business, financial condition and results of operations.





The Company’s authorized capital consists of 100,000,000 shares of common stock, of which 84,392,478 shares of common stock were outstanding at March 31, 2010.  The total of warrants exercisable into an aggregate of 11,143,372 shares of the Company’s common stock and stock options exercisable into an aggregate of 4,307,143 shares of the Company’s common stock at March 31, 2010 equal a total 15,450,515 shares of common stock underlying options and warrants that were outstanding at March 31, 2010.  The combination of the 84,392,478 shares of common stock outstanding and the 15,450,515 shares of potentially dilutive options and warrants outstanding at March 31, 2010 gives effect to a potential outstanding total of 99,842,993 of the authorized capital of 100,000,000 shares of common stock.   The expiration of over 2,000,000 warrants on May 31, 2010, due to their unlikely exercise, would decrease the potential amount of outstanding shares of the Company’s common stock.





Off-Balance Sheet Arrangements





As of March 31, 2010, we did not have any relationships with unconsolidated entities or financial partners, such as entities often referred to as structured finance or special purpose entities, that had been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.  As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.





Item4T. Controls and Procedures.





As of March 31, 2010, we carried out the evaluation of the effectiveness of our disclosure controls and procedures required by Rule 13a-15(e) under the Exchange Act under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.  Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2010, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.  There has been no change in our internal control over financial reporting identified in connection with this evaluation that occurred during our fiscal quarter ended March 31, 2010 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.





PART II – OTHER INFORMATION





Item  2. Unregistered Sales of Equity Securities and Use of Proceeds.





During the three months ended March 31, 2010, we sold the following securities without registration under the Securities Act of 1933, as amended (the “Securities Act”):




In January 2010, we sold 1,000,000 shares of our common stock and Class A warrants exercisable into 1,000,000 shares of our common stock to an accredited investor for aggregate gross proceeds of $40,000.  The Class A warrants have an exercise price of $0.04 per share, are exercisable during the period commencing on the date of grant and ending December 31, 2010, and expire at the end of the exercise period.





In February 2010, we sold 2,000,000 shares of our common stock to an accredited investor for aggregate gross proceeds of $40,000.




17




In February 2010, we sold 2,000,000 shares of our common stock and Class A warrants exercisable into 4,000,000 shares of our common stock to an accredited investor for aggregate gross proceeds of $40,000.  The Class A warrants have an exercise price of $0.02 per share, are exercisable during the period commencing on the date of grant and ending December 31, 2010, and expire at the end of the exercise period.





In March 2010, we completed a private offering of 450,000 shares of our common stock for aggregate cash consideration of $10,125 (the “First March 2010 Offering”).  The shares were sold at a purchase price of $0.0225 per share.  We agreed to use our reasonable best efforts to file a registration statement with the SEC by March 31, 2010 to register all of the shares of common stock issued in the offering.  The registration statement of which this prospectus is a part is being filed to satisfy our obligation to register these shares.





In March 2010, we completed a private offering of 3,200,000 shares of our common stock for aggregate cash consideration of $64,000 (the “Second March 2010 Offering”).  The shares were sold at a purchase price of $0.02 per share.  We paid finder fees consisting of 285,000 shares of our common stock.  We agreed to use our reasonable best efforts to file a registration statement with the SEC by March 31, 2010 to register all of the shares of common stock issued in the offering.  The registration statement of which this prospectus is a part is being filed to satisfy our obligation to register these shares.





Item5. Other Information.





The descriptions set forth below are included herewith for the purpose of providing an overview of the disclosure required under “Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers” of Form 8-K, previously filed on April 8, 2010, in connection with our issuance of stock and/or options to David M. Daniels, Alex Soufflas and Patricia S. Bathurst on March 31, 2010.





On March 31, 2010, the Company entered into a Securities Agreement with David M. Daniels, its Chief Executive Officer, pursuant to which it granted 1,180,612 shares of the Company’s common stock, $0.001 par value per share to Mr. Daniels.  The shares were issued in lieu of the payment of $17,690 of salary compensation earned by Mr. Daniels under the Employment Agreement, dated May 1, 2006, by and between the Company and Mr. Daniels, during the period commencing January 1, 2010 and ending January 31, 2010 and payable to Mr. Daniels as of January 31, 2010, and in part for the termination of the following stock options held by Mr. Daniels: (i) the stock option dated February 1, 2005 to acquire 2,500,000 shares of common stock at an exercise price of $0.40, (ii) the stock option dated December 12, 2006 to acquire 250,000 shares of common stock at an exercise price of $0.88, and (iii) the stock option dated March 25, 2008 to acquire 400,000 shares of common stock at an exercise price of $0.28.





On March 31, 2010, the Company entered into a Securities Agreement with Patricia S. Bathurst, its Vice President — Marketing,  pursuant to which it granted a stock option (the “Option”) to acquire 500,000 shares of common stock to Ms. Bathurst.  The Option was issued in lieu of the payment of $8,119 of salary compensation earned by Ms. Bathurst under the Employment Agreement, dated May 1, 2006, by and between the Company and Ms. Bathurst during the period commencing January 1, 2010 and ending January 31, 2010 and payable to Ms. Bathurst as of January 31, 2010, and in part for the termination of the following stock options held by Ms. Bathurst: (i) the stock option dated February 1, 2005 to acquire 2,500,000 shares of common stock at an exercise price of $0.40, (ii) the stock option dated December 12, 2006 to acquire 250,000 shares of common stock at an exercise price of $0.88, (iii) the stock option dated September 4, 2007 to acquire 400,000 shares of common stock at an exercise price of $0.50, and (iv) the stock option dated March 25, 2008 to acquire 400,000 shares of common stock at an exercise price of $0.28.  The Option is for a term of 10 years, has an exercise price of $0.045 per share and vested in full on the date of grant.





On March 31, 2010, the Company entered into a Securities Agreement with Alex Soufflas, its Chief Financial Officer and Executive Vice President,  pursuant to which it granted 382,112 shares of common stock to Mr. Soufflas.  The shares were issued in lieu of the payment of $14,765 of salary compensation earned by Mr. Soufflas under the Employment Agreement, dated February 1, 2006, by and between the Company and Mr. Soufflas, during the period commencing January 1, 2010 and ending January 31, 2010 and payable to Mr. Soufflas as of January 31, 2010.





The foregoing descriptions of the Securities Agreements and the Option do not purport to be complete and are qualified in their entirety by the terms of the Securities Agreements and Option filed as Exhibits 10.1 through 10.4 to our previously filed Form 8-K on April 8, 2010.





Item 6. Exhibits.




The following exhibits are included herein:




Exhibit No.

Exhibit31.1

Certification of Chief Executive Officer and Chief Financial Officer of the registrant required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended32.1

Certification of Chief Executive Officer and Chief Financial Officer of the registrant required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended


18


SIGNATURES





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.







NATIONAL HEALTH PARTNERS, INC.Date: May 17, 2010
/s/ David M. DanielsDavid M. DanielsChief Executive Officer andChief Financial Officer


19